Evaluation of a Novel Molecular NSCLC Classification System
- To validate a novel 4-protein signature's ability to subtype non-small cell lung cancer
(NSCLC) in a treatment-naive, multi-institutional cohort, CALGB 9761.
- To estimate the NSCLC misclassification rate in a multi-institutional clinical-trial
setting for stage 1 NSCLC (adenocarcinoma versus squamous cell).
OUTLINE: Archived tumor tissue samples are marked for regions appropriate for incorporation
into tissue microarray (TMA) and incubated with a cocktail of primary antibodies. Slides are
then stained and a series of high-resolution monochromatic images are captured by the
PM-2000 ™ microscope of each protein. Score of each specific protein is then calculated by
Automated Quantitative Analysis (AQUA).
A board-certified pathologist with a clinical focus in lung cancer reviews the hematoxylin
and eosin (H&E) and immunohistochemistry (IHC) slides and indicates the specific non-small
cell lung cancer subtype. Results are then compared with the primary reference subtype
captured by CALGB-9761 database.
Validation of a novel 4-protein signature's ability to subtype NSCLC
Daniel J. Boffa, MD
Smilow Cancer Hospital at Yale-New Haven